Drug evaluation of clevidipine for acute hypertension.
BACKGROUND
Clevidipine is an investigational agent undergoing late-stage clinical development to evaluate its potential as a novel short-acting intravenous agent for treating acute hypertension, either in hypertensive emergencies encountered in the emergency department and intensive care units, or in the perioperative period.


METHODS
Clevidipine has been evaluated in four Phase I studies, nine Phase II studies and six Phase III clinical studies. The patient populations studied include healthy volunteers, patients with essential hypertension, patients undergoing cardiac surgery, and patients presenting to the emergency department with hypertensive emergencies. Studies providing comparative data of clevidipine versus nitroglycerin, nicardipine or sodium nitroprusside are also available.


OBJECTIVE
This article reviews the results of clinical studies evaluating the pharmacological properties, clinical effects and safety profiles of clevidipine in various patient populations.


CONCLUSIONS
Clevidipine is an effective agent for reducing acute elevation in blood pressure in various settings, including hypertensive emergencies and perioperative hypertension with a good safety profile.
Noviawaty
Ika
I
University of Minnesota, Zeenat Qureshi Stroke Research Center, Department of Neurology, MMC 295, 420 Delaware St S.E., Minneapolis, MN 55455, USA.
Uzun
Guven
G
Qureshi
Adnan I
AI
D000208:Acute Disease; D000818:Animals; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D011725:Pyridines; C118563:clevidipine